Article Text

Download PDFPDF
Prophylactic efficacy on periprosthetic bone loss in calcar region after total hip arthroplasty of antiosteoporotic drugs: a network meta-analysis of randomised controlled studies
  1. Xi Chen1,
  2. Yu Shen1,
  3. Chenyi Ye2,
  4. Yishake Mumingjiang3,
  5. Jinwei Lu2,
  6. Yunxian Yu1,4
  1. 1Department of Public Health, Zhejiang University, Hangzhou, China
  2. 2Department of Orthopedic Surgery, Zhejiang University, Hangzhou, China
  3. 3Department of Orthopedics and Traumatology, Zhejiang Chinese Medical University, Hangzhou, China
  4. 4Department of Anesthesiology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China
  1. Correspondence to Dr Yunxian Yu, Department of Public Health, Zhejiang University - Zijingang Campus, Hangzhou 310058, China; yunxianyu{at}zju.edu.cn

Abstract

Objectives The aim of this study was to evaluate the effect of antiosteoporotic drugs on preventing periprosthetic bone loss in calcar 6 and 12 months after total hip arthroplasty.

Methods The network meta-analysis was conducted guided by the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline. A systematic literature search was conducted and 21 studies that enrolled a total of 955 patients with 9 antiosteoporotic drugs met the inclusion criteria. Network meta-analysis and conventional meta-analysis were carried out for calculating standard mean difference (SMD) and the surface under cumulative ranking curve (SUCRA) of the bone mineral density (BMD) in calcar (Gruen zone 7) as well as bone turnover markers (BTMs) including bone-specific alkaline phosphatase (BSAP) and collagen type I cross-linked N telopeptide (NTX) at 6 and 12 months between different antiosteoporotic drugs.

Results At 6 months after total hip arthroplasty, zoledronate (SUCRA=86.4%), risedronate (SUCRA=51.3%) and etidronate (SUCRA=44.5%) were effective in retaining BMD in calcar; zoledronate was significantly more effective than etidronate (SMD=0.65, 95% CI 0.03 to 1.27). Teriparatide (SUCRA=84.5%), denosumab (SUCRA=82.5%), zoledronate (SUCRA=69.2%), alendronate+alfacalcidol (SUCRA=66.2%) and etidronate (SUCRA=51.5%) were the top five drugs in retaining BMD in calcar at 12 months after total hip arthroplasty and the efficacy were comparable. After simultaneously excluding studies in which the prosthesis were cement and the drug dosages as well as treatment durations were inconsistent with those in treating osteoporosis, the above results were robust with the exception that alendronate showed significant efficacy compared with placebo (SMD=1.22, 95% CI 0.46 to 1.99) and was comparable with those effective drugs at 12 months. Long-term residual effect was corroborated only in etidronate, alendronate and zoledronate from previous studies. BTMs were significantly decreased as early as 6 months (SMD of BSAP −0.49, 95% CI −0.84 to −0.13; SMD of NTX −0.93, 95% CI −1.21 to −0.64) and sustained until 12 months (SMD of BSAP −0.27, 95% CI −0.50 to −0.03; SMD of NTX −0.84, 95% CI −1.11 to −0.56) during the prophylaxis.

Conclusions Antiosteoporotic drugs showed prophylactic efficacy on periprosthetic bone loss after total hip arthroplasty in calcar, the effectiveness varied. Zoledronate was the best recommendation due to its optimal efficacy both within 6 and 12 months as well as its residual effect in the long term. BTMs could be used as indicators for monitoring through the treatment. More head-to-head clinical trials are needed to confirm those findings.

  • periprosthetic bone loss
  • total hip arthroplasty
  • bone mineral density
  • bone turn-over markers
  • anti-osteoporotic drugs
View Full Text

Statistics from Altmetric.com

Footnotes

  • XC and YS contributed equally.

  • Contributors XC and YS conceived the study. XC and YS searched the literature and collected the data. CY, JL and YM performed the statistical analysis. XC and YS drafted the manuscript. YY reviewed the manuscript. XC revised the manuscript. All authors have read and approved the final paper.

  • Funding This study was funded by the Chinese National Natural Science Foundation (81973055) and the National Key Research and Development Program of China (2016YFC1305301).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. The data used to support the findings of this study are available from the corresponding author on request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.